Study to Assess the Efficacy and Safety of Raxone in LHON Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

199

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

March 29, 2021

Study Completion Date

March 29, 2021

Conditions
Leber's Hereditary Optic Neuropathy (LHON)
Interventions
DRUG

Idebenone

Trial Locations (29)

10003

New York Eye and Ear Infirmary, New York

22903

University of Virginia, Charlottesville

30322

Emory University Hospital, Atlanta

63110

Washington University, St Louis

94303

Stanford Byers Eye Institute, Stanford

Unknown

Retinal Consultants of Arizona, Phoenix

University of Colorado Health Eye Center, Aurora

Bethesda Neurology, LLC, Bethesda

AKH - Medizinische Universitaet Wien, Vienna

CHU Saint-Pierre, Brussels

Cliniques Universitaire Saint-Luc, Brussels

UZ Leuven - Campus Sint-Rafaël, Leuven

C. H. U. Sart Tilman, Liège

"UMHAT Alexandrovska EAD", Sofia

Friedrich-Baur-Institut, München

Università di Bologna-Clinica Neurologica-Dipartimento di Scienze Neurologiche, Bologna

Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego, Poznan

Samodzielny Publiczny Szpital Kliniczny Nr 2 PUM w Szczecinie, Szczecin

Samodzielny Publiczny Kliniczny Szpital Okulistyczny, Warsaw

Uniwersytecki Szpital Kliniczny, Wroclaw

Centro Hospitalar de São João, EPE, Porto

Institut Catala de Retina, Barcelona

Hospital Universitario Ramon y Cajal, Madrid

University Hospital of Wales, Cardiff

Moorfields Eye Hospital, London

Manchester Royal Eye Hospital, Manchester

Queen's Hospital, Romford

94040-2833

Palo Alto Medical Foundation, Palo Alto

31-501

SPZOZ Spital Uniwersytecki w Krakowie, Oddzial Kliniczny Okulistyki i Onkologii Okulistycznej, Krakow

Sponsors
All Listed Sponsors
lead

Santhera Pharmaceuticals

INDUSTRY

NCT02774005 - Study to Assess the Efficacy and Safety of Raxone in LHON Patients | Biotech Hunter | Biotech Hunter